Tushen Zhihe
Designs and optimises proteins, antibodies and cyclic peptides with its own and adapted open models on the ToursynClaw platform, tests them in automated wet labs, and is taking its own programmes toward IND filings.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-11-09Pre-A and Pre-A+Round
several hundred million yuan across two rounds
For: taking several in-house programmes toward IND filings, upgrading the ToursynClaw design platform, and growing the AI, R&D and business-development teams
Toward the clinicModels and platformHiring
Shanghai Kechuang Group led the Pre-A; the Pre-A+ names no lead. The split between the two rounds and the valuation are not disclosed.
Lead · Shanghai Kechuang GroupZhongsheng YinlingZhoushan TuyiJinding CapitalMegaRoboZero2IPO Holdings
Advisers: Kaicheng Capital (Exclusive financial adviser)
Announced by the company · news.pedaily.cn ↗On the timeline →
- 2025-09Angel+Round
around ten million yuan
For: R&D on its AI protein platform
Models and platform
CLS reports an earlier angel of several million yuan from Chengmei Capital and Guangzi Xingu, three months after founding, and four rounds in all by September 2025.
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.